Overview

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.
Phase:
Phase 2
Details
Lead Sponsor:
Oncology Specialists, S.C.
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Docetaxel
Sargramostim